Role of Rho-GTPases and their regulatory proteins in glomerular podocyte function

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 10, 2013, Pages 773-782

  Mouawad, Flaviana ^a   Tsui, Harmony ^a   Takano, Tomoko ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cytoskeleton; GTPase activating protein; Guanine nucleotide exchange factor; Nephrotic syndrome; Podocyte; Proteinuria; Rho GTPase

Indexed keywords

ACTIN; ANGIOTENSIN II; BETA3 INTEGRIN; DYNAMIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEPHRIN; PROTEIN CDC42; PROTEIN GDI 1; PROTEIN GDI 2; PROTEIN GDI 3; RAC1 PROTEIN; REGULATOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN;

ACTIN FILAMENT; ALBUMINURIA; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CONGENITAL NEPHROTIC SYNDROME; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; HIV ASSOCIATED NEPHROPATHY; HUMAN; MESANGIUM CELL; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY MECHANISM; REVIEW;

ACTIN CYTOSKELETON; ANIMALS; CDC42 GTP-BINDING PROTEIN; GLOMERULAR FILTRATION RATE; GTPASE-ACTIVATING PROTEINS; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MEMBRANE PROTEINS; MODELS, ANIMAL; PERMEABILITY; PODOCYTES; RAC1 GTP-BINDING PROTEIN; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84886014027     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2013-0135     Document Type: Review

References (119)

1. Abe, K., Rossman, K.L., Liu, B., Ritola, K.D., Chiang, D., Campbell, S.L., et al. 2000. Vav2 is an activator of Cdc42, Rac1, and RhoA. J. Biol. Chem. 275(14): 10141-10149. doi:10.1074/jbc.275.14.10141. PMID:10744696.
2. Advani, A.S., and Pendergast, A.M. 2002. Bcr-Abl variants: biological and clinical aspects. Leuk. Res. 26(8): 713-720. doi:10.1016/S0145-2126(01)00197-7. PMID: 12191565.
3. Akilesh, S., Suleiman, H., Yu, H., Stander, M.C., Lavin, P., Gbadegesin, R., et al. 2011. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J. Clin. Invest. 121(10): 4127-4137. doi:10.1172/JCI46458. PMID:21911940.
4. Asanuma, K., Yanagida-Asanuma, E., Faul, C., Tomino, Y., Kim, K., and Mundel, P. 2006. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat. Cell Biol. 8(5): 485-491. doi:10.1038/ ncb1400. PMID:16622418.
5. Attias, O., Jiang, R., Aoudjit, L., Kawachi, H., and Takano, T. 2010. Rac1 contributes to actin organization in glomerular podocytes. Nephron Exp. Nephrol. 114(3): e93-e106. doi:10.1159/000262317. PMID:19955829.
6. Bielek, H., Anselmo, A., and Dermardirossian, C. 2009. Morphological and pro-liferative abnormalitiesin renal mesangial cells lacking RhoGDI. Cell. Signal. 21(12): 1974-1983. doi:10.1016/j.cellsig.2009.09.008. PMID:19765647.
7. Boulter, E., Garcia-Mata, R., Guilluy, C., Dubash, A., Rossi, G., Brennwald, P.J., et al. 2010. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat. Cell Biol. 12(5): 477-483. doi:10.1038/ncb2049. PMID:20400958.
8. Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., et al. 2000. NPHS2, encoding the glomerular protein podocin, is mutated in auto-somal recessive steroid-resistant nephrotic syndrome. Nat. Genet.24(4): 349-354. doi:10.1038/74166. PMID:10742096.
9. Boyer, O., Benoit, G., Gribouval, O., Nevo, F., Tete, M.J., Dantal, J., et al. 2011a. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 22(2): 239-245. doi:10.1681/ASN. 2010050518. PMID:21258034.
10. Boyer, O., Nevo, F., Plaisier, E., Funalot, B., Gribouval, O., Benoit, G., et al. 2011b. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N. Engl. J. Med. 365(25): 2377-2388. doi:10.1056/NEJMoa1109122. PMID:22187985.
11. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12): 861-869. doi:10.1056/NEJMoa011161. PMID:11565518.
12. Brown, E.J., Schlondorff, J.S., Becker, D.J., Tsukaguchi, H., Tonna, S.J., Uscinski, A.L., et al. 2010. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat. Genet. 42(1): 72-76. doi:10.1038/ng.505. PMID:20023659.
13. Bruewer, M., Hopkins, A.M., Hobert, M.E., Nusrat, A., and Madara, J.L. 2004. RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. Am. J. Physiol. Cell Physiol. 287(2): C327-C335. doi:10.1152/ajpcell.00087. 2004. PMID:15044152.
14. Burridge, K., and Wennerberg, K. 2004. Rho and Rac take center stage. Cell, 116(2): 167-179. doi:10.1016/S0092-8674(04)00003-0. PMID:14744429.
15. Chen, Z.H., Qin, W.S., Zeng, C.H., Zheng, C.X., Hong, Y.M., Lu, Y.Z., et al. 2010. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 77(11): 974-988. doi:10.1038/ki.2010.41. PMID:20375980.
16. Chimini, G., and Chavrier, P. 2000. Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. Nat. Cell Biol. 2(10): E191-E196. doi:10.1038/35036454. PMID:11025683.
17. Daub, H., Gevaert, K., Vandekerckhove, J., Sobel, A., and Hall, A. 2001. Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J. Biol. Chem. 276(3): 1677-1680. doi: 10.1074/jbc.C000635200. PMID:11058583.
18. DerMardirossian, C., and Bokoch, G.M. 2005. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 15(7): 356-363. doi:10.1016/j.tcb. 2005.05.001. PMID:15921909.
19. Dryer, S.E., and Reiser, J. 2010. TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am. J. Physiol. Renal Physiol. 299(4): F689-F701. doi:10.1152/ajprenal.00298.2010. PMID: 20685822.
20. Endlich, N., Kress, K.R., Reiser, J., Uttenweiler, D., Kriz, W., Mundel, P., et al. 2001. Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12(3): 413-422. PMID:11181788.
21. Etienne-Manneville, S., and Hall, A. 2001. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell, 106(4): 489-498. doi:10.1016/S0092-8674(01)00471-8. PMID:11525734.
22. Fackler, O.T., Luo, W., Geyer, M., Alberts, A.S., and Peterlin, B.M. 1999. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol. Cell, 3(6): 729-739. doi:10.1016/S1097-2765(01)80005-8. PMID: 10394361.
23. Faul, C., Asanuma, K., Yanagida-Asanuma, E., Kim, K., and Mundel, P.2007. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17(9): 428-437. doi:10.1016/j.tcb.2007.06. 006. PMID:17804239.
24. Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y.H., Franz, S., Delfgaauw, J., et al. 2008. The actin cytoskeleton of kidney podocytes is adirect targetof the antiproteinuric effect of cyclosporine A. Nat. Med. 14(9): 931-938. doi:10.1038/ nm.1857. PMID:18724379.
25. Gao, S.Y., Li, C.Y., Chen, J., Pan, L., Saito, S., Terashita, T., et al. 2004. Rho-ROCK signal pathway regulates microtubule-based process formation of cultured podocytes: inhibition of ROCK promoted process elongation. Nephron Exp. Nephrol. 97(2): e49-e61. doi:10.1159/000078406. PMID:15218323.
26. Gao, S.Y., Li, C.Y., Shimokawa, T., Terashita, T., Matsuda, S., Yaoita, E., et al. 2007. Rho-family small GTPases are involved in forskolin-induced cell-cell contact formation of renal glomerular podocytes in vitro. Cell Tissue Res. 328(2): 391-400. doi:10.1007/s00441-006-0365-3. PMID:17265067.
27. Garcia-Mata, R., Boulter, E., and Burridge, K. 2011. The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat. Rev. Mol. Cell Biol. 12(8): 493-504. doi:10.1038/nrm3153. PMID:21779026.
28. George, B., Verma, R., Soofi, A.A., Garg, P., Zhang, J., Park, T.J., et al. 2012. Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J. Clin. Invest. 122(2): 674-692. doi: 10.1172/JCI60070. PMID:22251701.
29. Gojo, A., Utsunomiya, K., Taniguchi, K., Yokota, T., Ishizawa, S., Kanazawa, Y., et al. 2007. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropa-thy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 568(1-3): 242-247. doi:10.1016/j.ejphar.2007.04.011. PMID:17511984.
30. Greka, A., and Mundel, P. 2012. Cell biology and pathology of podocytes. Annu. Rev. Physiol. 74: 299-323. doi:10.1146/annurev-physiol-020911-153238. PMID: 22054238.
31. Gupta, I.R., Baldwin, C., Auguste, D., Ha, K.C., El Andalousi, J., Fahiminiya, S., et al. 2013. ARHGDIA: a novel gene implicated in nephrotic syndrome. J. Med. Genet. 50: 330-338. doi:10.1136/jmedgenet-2012-101442. PMID:23434736.
32. Hall, A. 1998. Rho GTPases and the actin cytoskeleton. Science, 279(5350): 509-514. doi:10.1126/science.279.5350.509. PMID:9438836.
33. Han, H., Bearss, D.J., Browne, L.W., Calaluce, R., Nagle, R.B., and Von Hoff, D.D. 2002. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62(10): 2890-2896. PMID:12019169.
34. Hayashi, K., Wakino, S., Kanda, T., Homma, K., Sugano, N., and Saruta, T. 2006. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J. Pharmacol. Sci. 100(1): 29-33. doi:10.1254/jphs.FMJ05003X6. PMID:16397371.
35. Hidaka, T., Suzuki, Y., Yamashita, M., Shibata, T., Tanaka, Y., Horikoshi, S., et al. 2008. Amelioration of crescentic glomerulonephritis by RhoA kinase inhibitor, Fasudil, through podocyte protection and prevention of leukocyte migration. Am. J. Pathol. 172(3): 603-614. doi:10.2353/ajpath.2008.070196. PMID: 18245810.
36. Hsu, H.H., Hoffmann, S., Endlich, N., Velic, A., Schwab, A., Weide, T., et al. 2008. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J. Mol. Med. 86(12): 1379-1394. doi:10.1007/s00109-008-0399-y. PMID:18773185.
37. Ishikawa, Y., Nishikimi, T., Akimoto, K., Ishimura, K., Ono, H., and Matsuoka, H. 2006. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension, 47(6): 1075-1083. doi: 10.1161/01.HYP.0000221605.94532.71. PMID:16636194.
38. Jalink, K., van Corven, E.J., Hengeveld, T., Morii, N., Narumiya, S., and Moolenaar, W.H. 1994. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J. Cell Biol. 126(3): 801-810. doi:10.1083/ jcb.126.3.801. PMID:8045941.
39. Jeruschke, S., Buscher, A.K., Oh, J., Saleem, M.A., Hoyer, P.F., Weber, S., et al. 2013. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PLoS One, 8(2): e55980. doi:10.1371/journal.pone.0055980. PMID:23418489.
40. 2+ and RhoA activation. Exp. Biol. Med. (Maywood), 236(2): 184-193. doi:10.1258/ebm.2010. 010237. PMID:21321315.
41. Johnstone, D.B., and Holzman, L.B. 2006. Clinical impact of research on the podocyte slit diaphragm. Nat. Clin. Pract. Nephrol. 2(5): 271-282. doi:10.1038/ ncpneph0180. PMID:16932440.
42. Jones, M.B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L.A., Kohn, E.C., et al. 2002. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics, 2(1): 76-84. doi:10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F. PMID:11788994.
43. Kaibuchi, K., Kuroda, S., and Amano, M. 1999. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68: 459-486. doi:10.1146/annurev.biochem.68.1.459. PMID: 10872457.
44. Kanda, T., Wakino, S., Hayashi, K., Homma, K., Ozawa, Y., and Saruta, T. 2003. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrecto-mized spontaneously hypertensive rats. Kidney Int. 64(6): 2009-2019. doi:10. 1046/j.1523-1755.2003.00300.x. PMID:14633123.
45. Kang, Y.S., Li, Y., Dai, C., Kiss, L.P., Wu, C., and Liu, Y. 2010. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int. 78(4): 363-373. doi:10.1038/ki.2010.137. PMID: 20505657.
46. Kestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., et al. 1998. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol. Cell, 1(4): 575-582. doi:10.1016/ S1097-2765(00)80057-X. PMID:9660941.
47. Khoshnoodi, J., Sigmundsson, K., Ofverstedt, L.G., Skoglund, U., Obrink, B., Wartiovaara, J., et al. 2003. Nephrin promotes cell-cell adhesion through homophilic interactions. Am. J. Pathol. 163(6): 2337-2346. doi:10.1016/S0002-9440(10)63590-0. PMID:14633607.
48. Kikuchi, Y., Yamada, M., Imakiire, T., Kushiyama, T., Higashi, K., Hyodo, N., et al. 2007. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 192(3): 595-603. doi:10.1677/JOE-06-0045. PMID:17332527.
49. + (BKCa) channels: role in BKCa trafficking to the surface of cultured podocytes. Mol. Pharmacol. 75(3): 466-477. doi:10.1124/mol.108.051912. PMID:19052171.
50. Kobayashi, N., Gao, S.Y., Chen, J., Saito, K., Miyawaki, K., Li, C.Y., et al. 2004. Process formation of the renal glomerular podocyte: is there common molecular machinery for processes of podocytes and neurons? Anat. Sci. Int. 79(1): 1-10. doi:10.1111/j.1447-073x.2004.00066.x. PMID:15088787.
51. Komers, R., Oyama, T.T., Beard, D.R., Tikellis, C., Xu, B., Lotspeich, D.F., et al. 2011. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int. 79(4): 432-442. doi:10.1038/ki. 2010.428. PMID:20962741.
52. Koshikawa, S., Nishikimi, T., Inaba, C., Akimoto, K., and Matsuoka, H. 2008. Fasudil, a Rho-kinase inhibitor, reverses l-NAME exacerbated severe ne-phrosclerosis in spontaneously hypertensive rats. J. Hypertens. 26(9): 1837-1848. doi:10.1097/HJH.0b013e328305086c. PMID:18698220.
53. Kourlas, P.J., Strout, M.P., Becknell, B., Veronese, M.L., Croce, C.M., Theil, K.S., et al. 2000. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 97(5): 2145-2150. doi:10.1073/pnas.040569197. PMID:10681437.
54. Krendel, M., Zenke, F.T., and Bokoch, G.M. 2002. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat. Cell Biol. 4(4): 294-301. doi:10.1038/ncb773. PMID:11912491.
55. Kumagai, T., Mouawad, F., and Takano, T. 2012. Pathogenesis of common glo-merular diseases-role of the podocyte cytoskeleton. Cell Health Cytoskelet. (4): 103-118. doi:10.2147/CHC.S35534.
56. Kurokawa, K., Nakamura, T., Aoki, K., and Matsuda, M. 2005. Mechanism and role of localized activation of Rho-family GTPases in growth factor-stimulated fibroblasts and neuronal cells. Biochem. Soc. Trans. 33(Pt. 4): 631-634. PMID:16042560.
57. Kutsche, K., Yntema, H., Brandt, A., Jantke, I., Nothwang, H.G., Orth, U., et al. 2000. Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho GTPases, in patients with X-linked mental retardation. Nat. Genet. 26(2): 247-250. doi:10.1038/80002. PMID:11017088.
58. Lal, M.A., and Tryggvason, K. 2012. Knocking out podocyte rho GTPases: and the winner is. J. Am. Soc. Nephrol. 23(7): 1128-1129. doi:10.1681/ASN.2012050494. PMID:22677549.
59. Lecian, D., Demova, H., Lodererova, A., Zdychova, J., Kluckova, H., Teplan, V., et al. 2006. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press. Res. 29(3): 135-143. doi:10.1159/000094988. PMID:16899993.
60. Leeuwen, F.N., Kain, H.E., Kammen, R.A., Michiels, F., Kranenburg, O.W., and Collard, J.G. 1997. The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. J. Cell Biol. 139(3): 797-807. doi:10.1083/jcb.139.3.797. PMID:9348295.
61. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., et al. 2001. Renoprotective effectofthe angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345(12): 851-860. doi:10.1056/NEJMoa011303. PMID:11565517.
62. Liu, Y., Echtermeyer, F., Thilo, F., Theilmeier, G., Schmidt, A., Schulein, R., et al. 2012. The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via RhoA/Rho-associated protein kinase signaling. Arterioscler. Thromb. Vasc. Biol. 32(2): 378-385. doi:10.1161/ATVBAHA.111. 241018. PMID:22155451.
63. Lu, T.C., He, J.C., Wang, Z.H., Feng, X., Fukumi-Tominaga, T., Chen, N., etal. 2008. HIV-1 Nef disrupts the podocyte actin cytoskeleton byinteracting with diaphanous interacting protein. J. Biol. Chem. 283(13): 8173-8182. doi:10.1074/jbc. M708920200. PMID:18234668.
64. Luo, L. 2000. Rho GTPases in neuronal morphogenesis. Nat. Rev. Neurosci. 1(3): 173-180. doi:10.1038/35044547. PMID:11257905.
65. Moon, S.Y., and Zheng, Y. 2003. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 13(1): 13-22. doi:10.1016/S0962-8924(02)00004-1. PMID: 12480336.
66. Morigi, M., Buelli, S., Angioletti, S., Zanchi, C., Longaretti, L., Zoja, C., et al. 2005. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am. J. Pathol. 166(5): 1309-1320. doi:10.1016/S0002-9440(10) 62350-4. PMID:15855633.
67. Mueller, B.K. 1999. Growth cone guidance: first steps towards a deeper understanding. Annu. Rev. Neurosci. 22: 351-388. doi:10.1146/annurev.neuro.22.1. 351. PMID:10202543.
68. Mundel, P., and Reiser, J. 2010. Proteinuria: an enzymatic disease of the podo-cyte? Kidney Int. 77(7): 571-580. doi:10.1038/ki.2009.424. PMID:19924101.
69. Mundel, P., Reiser, J., Zuniga Mejia Borja, A., Pavenstadt, H., Davidson, G.R., Kriz, W., et al. 1997. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp. Cell Res. 236(1): 248-258. doi:10.1006/ excr.1997.3739. PMID:9344605.
70. Nagase, M., and Fujita, T. 2013. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat. Rev. Nephrol. 9(2): 86-98. doi:10.1038/ nrneph.2012.282. PMID:23296296.
71. Nishikimi, T., Akimoto, K., Wang, X., Mori, Y., Tadokoro, K., Ishikawa, Y., et al. 2004. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J. Hypertens. 22(9): 1787-1796. doi:10.1097/00004872-200409000-00024. PMID:15311108.
72. Nishikimi, T., Koshikawa, S., Ishikawa, Y., Akimoto, K., Inaba, C., Ishimura, K., et al. 2007. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J. Hypertens. 25(5): 1053-1063. doi:10.1097/HJH.0b013e3280825440. PMID:17414670.
73. Orrico, A., Galli, L., Falciani, M., Bracci, M., Cavaliere, M.L., Rinaldi, M.M., et al. 2000. Amutation inthe pleckstrin homology (PH) domain oftheFGD1 gene in an Italian family with faciogenital dysplasia (Aarskog-Scott syndrome). FEBS Lett. 478(3): 216-220. doi:10.1016/S0014-5793(00)01857-3. PMID:10930571.
74. Ozawa, Y., and Kobori, H. 2007. Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. Am. J. Physiol. Renal Physiol. 293(1): F100-F109. doi:10.1152/ajprenal.00520.2006. PMID:17409276.
75. Pasteris, N.G., Cadle, A., Logie, L.J., Porteous, M.E., Schwartz, C.E., Stevenson, R.E., et al. 1994. Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucle-otide exchange factor. Cell, 79(4): 669-678. doi:10.1016/0092-8674(94)90552-5. PMID:7954831.
76. Peng, F., Wu, D., Gao, B., Ingram, A.J., Zhang, B., Chorneyko, K., et al. 2008. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes, 57(6): 1683-1692. doi:10.2337/db07-1149. PMID:18356410.
77. Reiser, J., Kriz, W., Kretzler, M., and Mundel, P. 2000. The glomerular slit diaphragm is a modified adherens junction. J. Am. Soc. Nephrol. 11(1): 1-8. PMID:10616834.
78. Reiser, J., Polu, K.R., Moller, C.C., Kenlan, P., Altintas, M.M., Wei, C., et al. 2005. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat. Genet. 37(7): 739-744. doi:10.1038/ng1592. PMID: 15924139.
79. Rossman, K.L., Der, C.J., and Sondek, J. 2005. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6(2), 167-180. doi:10.1038/nrm1587. PMID:15688002.
80. Sahai, E., and Marshall, C.J. 2002. RHO-GTPases and cancer. Nat. Rev. Cancer, 2(2): 133-142. doi:10.1038/nrc725. PMID:12635176.
81. Schafer, D.A. 2004. Regulating actin dynamics at membranes: a focus on dy-namin. Traffic, 5(7): 463-469. doi:10.1111/j.1600-0854.2004.00199.x. PMID: 15180823.
82. Schmidt, A., and Hall, A. 2002. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 16(13): 1587-1609. doi:10.1101/gad. 1003302. PMID:12101119.
83. Scott, R.P., Hawley, S.P., Ruston, J., Du, J., Brakebusch, C., Jones, N., et al. 2012. Podocyte-specific loss of cdc42 leads to congenital nephropathy. J. Am. Soc. Nephrol. 23(7): 1149-1154. doi:10.1681/ASN.2011121206. PMID:22518006.
84. Sever, S., Altintas, M.M., Nankoe, S.R., Moller, C.C., Ko, D., Wei, C., et al. 2007. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 117(8): 2095-2104. doi:10. 1172/JCI32022. PMID:17671649.
85. Shankland, S.J. 2006. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 69(12): 2131-2147. doi:10.1038/sj.ki.5000410. PMID:16688120.
86. Shankland, S.J., Pippin, J.W., Reiser, J., and Mundel, P. 2007. Podocytes in culture: past, present, and future. Kidney Int. 72(1): 26-36. doi:10.1038/sj.ki. 5002291. PMID:17457377.
87. Shibata, S., Nagase, M., and Fujita, T. 2006. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J. Am. Soc. Nephrol. 17(3): 754-764. doi:10.1681/ASN.2005050571. PMID:16452496.
88. Shibata, S., Nagase, M., Yoshida, S., Kawarazaki, W., Kurihara, H., Tanaka, H., et al. 2008. Modification of mineralocorticoid receptor function by Rac1 GT-Pase: implication in proteinuric kidney disease. Nat. Med. 14(12): 1370-1376. doi:10.1038/nm.1879. PMID:19029984.
89. Shibata, S., Mu, S., Kawarazaki, H., Muraoka, K., Ishizawa, K., Yoshida, S., et al. 2011. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J. Clin. Invest. 121(8): 3233-3243. doi:10.1172/JCI43124. PMID:21765214.
90. Shimojima, K., Sugawara, M., Shichiji, M., Mukaida, S., Takayama, R., Imai, K., et al. 2011. Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy. J. Hum. Genet. 56(8): 561-565. doi:10.1038/jhg.2011.58. PMID:21633362.
91. Smith, H.W., and Marshall, C.J. 2010. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11(1): 23-36. doi:10.1038/nrm2821. PMID:20027185.
92. Sosa, M.S., Lopez-Haber, C., Yang, C., Wang, H., Lemmon, M.A., Busillo, J.M., et al. 2010. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol. Cell, 40(6): 877-892. doi:10.1016/j.molcel.2010. 11.029. PMID:21172654.
93. Southgate, L., Machado, R.D., Snape, K.M., Primeau, M., Dafou, D., Ruddy, D.M., et al. 2011. Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies. Am. J. Hum. Genet. 88(5): 574-585. doi:10.1016/j.ajhg.2011.04.013. PMID:21565291.
94. Stirzaker, R., Biswas, P., Gupta, S., Song, L., Bhagat, G., and Pernis, A. 2012. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus, 21(6): 656-661. doi:10.1177/0961203312436862. PMID:22345122.
95. Sun, G.P., Kohno, M., Guo, P., Nagai, Y., Miyata, K., Fan, Y.Y., et al. 2006. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J. Am. Soc. Nephrol. 17(8): 2193-2201. doi:10.1681/ASN.2005121375. PMID:16790507.
96. Sun, H., Schlondorff, J.S., Brown, E.J., Higgs, H.N., and Pollak, M.R. 2011. Rho activation of mDia formins is modulated by an interaction with inverted formin 2 (INF2). Proc. Natl. Acad. Sci. U.S.A. 108(7): 2933-2938. doi:10.1073/ pnas.1017010108. PMID:21278336.
97. Sunamoto, M., Husain, M., He, J.C., Schwartz, E.J., and Klotman, P.E. 2003. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int. 64(5): 1695-1701. doi:10.1046/j.1523-1755.2003.00283.x. PMID:14531802.
98. Suzuki, H., Yamamoto, T., Fujigaki, Y., Eguchi, S., and Hishida, A. 2011. Comparison of ROCK and EGFR activation pathways in the progression of glomer-ular injuries in AngII-infused rats. Ren. Fail. 33(10): 1005-1012. doi:10.3109/ 0886022X.2011.618923. PMID:22013934.
99. Tapper, J., Kettunen, E., El-Rifai, W., Seppala, M., Andersson, L.C., and Knuutila, S. 2001. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 128(1): 1-6. doi:10.1016/S0165-4608(01) 00386-7. PMID:11454421.
100. Tcherkezian, J., and Lamarche-Vane, N. 2007. Current knowledge of the large RhoGAP family of proteins. Biol. Cell, 99(2): 67-86. doi:10.1042/BC20060086. PMID:17222083.
101. Tian, D., Jacobo, S.M., Billing, D., Rozkalne, A., Gage, S.D., Anagnostou, T., et al. 2010. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci. Signal. 3(145): ra77. doi:10.1126/scisignal.2001200. PMID:20978238.
102. Togawa, A., Miyoshi, J., Ishizaki, H., Tanaka, M., Takakura, A., Nishioka, H., et al. 1999. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene, 18(39): 5373-5380. doi:10.1038/sj.onc. 1202921. PMID:10498891.
103. Venkatachalam, K., and Montell, C. 2007. TRP channels. Annu. Rev. Biochem.76: 387-417. doi:10.1146/annurev.biochem.75.103004.142819. PMID:17579562.
104. Versteilen, A.M., Blaauw, N., Di Maggio, F., Groeneveld, A.B., Sipkema, P., Musters, R.J., et al. 2011. rho-Kinase inhibition reduces early microvascular leukocyte accumulation in the rat kidney following ischemia-reperfusion injury: roles of nitric oxide and blood flow. Nephron Exp. Nephrol. 118(4): e79-e86. doi:10.1159/000322605. PMID:21311198.
105. Wang, L., Ellis, M.J., Fields, T.A., Howell, D.N., and Spurney, R.F. 2008. Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin ami-nonucleoside nephrosis. Kidney Blood Press. Res. 31(2): 111-121. doi:10.1159/ 000121531. PMID:18367845.
106. Wang, L., Ellis, M.J., Gomez, J.A., Eisner, W., Fennell, W., Howell, D.N., et al. 2012a. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int. 81: 1075-1085. doi:10.1038/ki.2011.472. PMID:22278020.
107. Wang, W., Wang, Y., Long, J., Wang, J., Haudek, S.B., Overbeek, P., et al. 2012b. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 15(2): 186-200. doi: 10.1016/j.cmet.2012.01.009. PMID:22326220.
108. Wei, C., Moller, C.C., Altintas, M.M., Li, J., Schwarz, K., Zacchigna, S., et al. 2008. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14(1): 55-63. doi:10.1038/nm1696. PMID:18084301.
109. Wei, C., El Hindi, S., Li, J., Fornoni, A., Goes, N., Sageshima, J., et al. 2011. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17(8): 952-960. doi:10.1038/nm.2411. PMID:21804539.
110. Welsh, G.I., and Saleem, M.A. 2011. The podocyte cytoskeleton: key to a functioning glomerulus in health and disease. Nat. Rev. Nephrol. 8(1): 14-21. doi:10. 1038/nrneph.2011.151. PMID:22025085.
111. Wennmann, D.O., Hsu, H.H., and Pavenstadt, H. 2012. The renin-angiotensin-aldosterone system in podocytes. Semin. Nephrol.32(4): 377-384. doi:10.1016/ j.semnephrol.2012.06.009. PMID:22958492.
112. Williams, J.M., Johnson, A.C., Stelloh, C., Dreisbach, A.W., Franceschini, N., Regner, K.R., et al. 2012. Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat: novelty and significance. Hypertension, 60(5): 1157-1168. doi:10.1161/HYPERTENSIONAHA.112.199240. PMID: 22987919.
113. Winn, M.P., Conlon, P.J., Lynn, K.L., Farrington, M.K., Creazzo, T., Hawkins, A.F., et al. 2005. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science, 308(5729): 1801-1804. doi:10.1126/ science.1106215. PMID:15879175.
114. Yanagida-Asanuma, E., Asanuma, K., Kim, K., Donnelly, M., Young Choi, H., Hyung Chang, J., et al. 2007. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. Am. J. Pathol. 171(2): 415-427. doi:10.2353/ajpath.2007.070075. PMID:17569780.
115. Yuen, D.A., Stead, B.E., Zhang, Y., White, K.E., Kabir, M.G., Thai, K., et al. 2012. eNOS deficiency predisposes podocytes to injury in diabetes. J. Am. Soc. Nephrol. 23(11): 1810-1823. doi:10.1681/ASN.2011121170. PMID:22997257.
116. Zhang, H., Cybulsky, A.V., Aoudjit, L., Zhu, J., Li, H., Lamarche-Vane, N., et al. 2007. Role of Rho-GTPases in complement-mediated glomerular epithelial cellinjury. Am. J. Physiol. RenalPhysiol. 293(1):F148-F156. doi:10.1152/ajprenal. 00294.2006. PMID:17376765.
117. Zhu, J., Sun, N., Aoudjit, L., Li, H., Kawachi, H., Lemay, S., et al. 2008. Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int. 73(5): 556-566. doi:10.1038/sj.ki.5002691. PMID:18033240.
118. Zhu, L., Jiang, R., Aoudjit, L., Jones, N., and Takano, T. 2011. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 22(9): 1621-1630. doi:10.1681/ASN.2010111146. PMID:21804090.
119. Zhu, L., Qi, X.Y., Aoudjit, L., Mouawad, F., Baldwin, C., Nattel, S., et al. 2013. Nuclear factor of activated T-cells mediates RhoA-induced fibronectin up-regulation in glomerular podocytes. Am. J. Physiol. Renal Physiol. 34(7): F849-F862. doi:10.1152/ajprenal.00495.2012. PMID:23389455.